Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2198 from our risk checks.
Guangdong Jiaying Pharmaceutical Co., Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.71 |
52 Week High | CN¥9.15 |
52 Week Low | CN¥4.67 |
Beta | 0.72 |
1 Month Change | 16.09% |
3 Month Change | -6.55% |
1 Year Change | -9.93% |
3 Year Change | 28.05% |
5 Year Change | -18.37% |
Change since IPO | 52.50% |
Recent News & Updates
Shareholder Returns
2198 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 1.4% | -1.6% | -0.03% |
1Y | -9.9% | -8.6% | -14.2% |
Return vs Industry: 002198 underperformed the CN Pharmaceuticals industry which returned -8.6% over the past year.
Return vs Market: 002198 exceeded the CN Market which returned -14.2% over the past year.
Price Volatility
2198 volatility | |
---|---|
2198 Average Weekly Movement | 7.0% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 8.1% |
10% most volatile stocks in CN Market | 11.3% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002198's share price has been volatile over the past 3 months.
Volatility Over Time: 002198's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 732 | n/a | https://www.gdjyzy.com.cn |
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese patient medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also offers provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablets (capsules), Shufenghuoluo tablets, Tiaomenghuoxue tablets, and etc. Guangdong Jiaying Pharmaceutical Co., Ltd.
Guangdong Jiaying Pharmaceutical Co., Ltd Fundamentals Summary
2198 fundamental statistics | |
---|---|
Market cap | CN¥3.41b |
Earnings (TTM) | CN¥46.58m |
Revenue (TTM) | CN¥621.81m |
73.1x
P/E Ratio5.5x
P/S RatioIs 2198 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2198 income statement (TTM) | |
---|---|
Revenue | CN¥621.81m |
Cost of Revenue | CN¥222.45m |
Gross Profit | CN¥399.36m |
Other Expenses | CN¥352.78m |
Earnings | CN¥46.58m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 27, 2024
Earnings per share (EPS) | 0.092 |
Gross Margin | 64.23% |
Net Profit Margin | 7.49% |
Debt/Equity Ratio | 0% |
How did 2198 perform over the long term?
See historical performance and comparison